| 1 | Closing the policy gap in diabetes care for individuals with advanced CKD | 1.7 | 9 | Citations (PDF) |
| 2 | Baseline Characteristics of the DISCOVER CKD Prospective Cohort | 2.7 | 5 | Citations (PDF) |
| 3 | The soluble guanylate cyclase activator runcaciguat significantly improves albuminuria in patients with chronic kidney disease: a randomized placebo-controlled clinical trial | 0.7 | 18 | Citations (PDF) |
| 4 | Medication review interventions for adults living with advanced chronic kidney disease: A scoping review | 1.5 | 3 | Citations (PDF) |
| 5 | Beyond glycated haemoglobin: Modelling contemporary management of type 2 diabetes with the updated Cardiff model | 3.2 | 2 | Citations (PDF) |
| 6 | Research recommendations from the 2024 Breakthrough T1D, Diabetes UK and Kidney Research
UK
, diabetes and kidney disease expert workshop | 1.7 | 0 | Citations (PDF) |
| 7 | Effects of combined treatment with zibotentan and dapagliflozin compared to dapagliflozin alone in patients with diabetic and non‐diabetic chronic kidney disease | 3.2 | 6 | Citations (PDF) |
| 8 | Anticoagulation Timing in Acute Stroke With Atrial Fibrillation According to Chronic Kidney Disease: The OPTIMAS Trial | 4.4 | 2 | Citations (PDF) |
| 9 | Patient-reported outcome measures for fatigue in patients with chronic kidney disease: a systematic review | 1.2 | 3 | Citations (PDF) |
| 10 | Glucose‐lowering treatment pathways of individuals with chronic kidney disease and type 2 diabetes according to the Kidney Disease: Improving Global Outcomes 2012 risk classification | 1.7 | 1 | Citations (PDF) |
| 11 | Efficacy and Safety of Dapagliflozin in Patients With Chronic Kidney Disease Across the Spectrum of Frailty | 2.5 | 38 | Citations (PDF) |
| 12 | Effect of Dialysate and Plasma Sodium on Mortality in a Global Historical Hemodialysis Cohort | 0.3 | 24 | Citations (PDF) |
| 13 | VALOR-CKD: A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial Evaluating Veverimer in Slowing Progression of CKD in Patients with Metabolic Acidosis | 0.3 | 19 | Citations (PDF) |
| 14 | Dapagliflozin in chronic kidney disease: cost-effectiveness beyond the DAPA-CKD trial | 2.5 | 21 | Citations (PDF) |
| 15 | Associations With Baseline Blood Pressure Control in NURTuRE-CKD | 2.1 | 1 | Citations (PDF) |
| 16 | Identifying individuals at risk of needing CKD associated medications in a European kidney disease cohort | 1.5 | 0 | Citations (PDF) |
| 17 | Randomised, blinded, cross-over evaluation of the palatability of and preference for different potassium binders in participants with chronic hyperkalaemia in the USA, Canada and Europe: the APPETIZE study | 1.2 | 8 | Citations (PDF) |
| 18 | Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis | 13.1 | 181 | Citations (PDF) |
| 19 | Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cause-Specific Cardiovascular Death in Patients with CKD | 3.0 | 1 | Citations (PDF) |
| 20 | A note on performance metrics for the Kidney Failure Risk Equation | 0.7 | 2 | Citations (PDF) |
| 21 | Clinical Outcomes in Patients with CKD and Rapid or Non-rapid eGFR Decline: A Report from the DISCOVER CKD Retrospective Cohort | 2.7 | 17 | Citations (PDF) |
| 22 | #2755 NURTuRE-CKD: outcomes by primary renal diagnosis | 0.7 | 0 | Citations (PDF) |
| 23 | Hyperkalemia Burden and Treatment Pathways in Patients with CKD: Findings From the DISCOVER CKD Retrospective Cohort | 1.4 | 4 | Citations (PDF) |
| 24 | Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in Kidney Disease | 5.2 | 14 | Citations (PDF) |
| 25 | IMPACT CKD: Holistic Disease Model Projecting 10-Year Population Burdens | 2.1 | 23 | Citations (PDF) |
| 26 | Organisational initiatives to improve care in the prevention and management of cardiometabolic conditions: A scoping review | 2.2 | 9 | Citations (PDF) |
| 27 | First interim results from FINE-REAL: a prospective, non-interventional, phase 4 study providing insights into the use and safety of finerenone in a routine clinical setting | 1.2 | 20 | Citations (PDF) |
| 28 | High-dose intravenous iron reduces myocardial infarction in patients on haemodialysis | 5.7 | 15 | Citations (PDF) |
| 29 | Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease | 7.3 | 19 | Citations (PDF) |
| 30 | Major cardiovascular events and subsequent risk of kidney failure with replacement therapy: a CKD Prognosis Consortium study | 2.6 | 30 | Citations (PDF) |
| 31 | Design and rationale of FINE-REAL: A prospective study of finerenone in clinical practice | 1.8 | 27 | Citations (PDF) |
| 32 | Health Care Resource Utilization and Related Costs of Patients With CKD From the United States: A Report From the DISCOVER CKD Retrospective Cohort | 2.1 | 28 | Citations (PDF) |
| 33 | The Role of Expert Opinion in Projecting Long-Term Survival Outcomes Beyond the Horizon of a Clinical Trial | 2.7 | 9 | Citations (PDF) |
| 34 | Effectiveness and Safety of Dapagliflozin for Black and White Patients With Chronic Kidney Disease in North and South America | 5.2 | 9 | Citations (PDF) |
| 35 | Effects of Dapagliflozin in Chronic Kidney Disease, With and Without Other Cardiovascular Medications: DAPA‐CKD Trial | 3.1 | 29 | Citations (PDF) |
| 36 | #4167 THE HEALTH, SOCIOECONOMIC AND ENVIRONMENTAL IMPACT OF CKD IN THE UK: BUILDING A CONCEPTUAL FRAMEWORK | 0.7 | 0 | Citations (PDF) |
| 37 | #3704 EU REGION-SPECIFIC CARDIOVASCULAR EVENT DATA FOR DAPRODUSTAT IN ASCEND-D AND ASCEND-ND | 0.7 | 0 | Citations (PDF) |
| 38 | #3790 BASELINE BLOOD PRESSURE CONTROL IN THE NURTURE CKD COHORT STUDY | 0.7 | 0 | Citations (PDF) |
| 39 | Hypertension and small vessel disease: do the drugs work? | 0.6 | 1 | Citations (PDF) |
| 40 | Development and Validation of a New Hierarchical Composite End Point for Clinical Trials of Kidney Disease Progression | 0.3 | 42 | Citations (PDF) |
| 41 | Effect of SGLT2 Inhibitors on Discontinuation of Renin–angiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD Trials | 0.3 | 41 | Citations (PDF) |
| 42 | Interim Results from FINE-REAL: A Prospective Study Providing Insights into the Use of Finerenone in Routine Clinical Settings | 0.3 | 2 | Citations (PDF) |
| 43 | Long-Term Safety of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in CKD: A Systematic Review and Meta-Analysis of Randomized Trials | 0.3 | 0 | Citations (PDF) |
| 44 | Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial | 0.7 | 18 | Citations (PDF) |
| 45 | Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial | 1.0 | 53 | Citations (PDF) |
| 46 | The burden of subclinical cardiovascular disease in children and young adults with chronic kidney disease and on dialysis | 2.5 | 14 | Citations (PDF) |
| 47 | A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function | 4.6 | 86 | Citations (PDF) |
| 48 | Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial | 0.7 | 100 | Citations (PDF) |
| 49 | Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials | 12.5 | 71 | Citations (PDF) |
| 50 | Quételet (body mass) index and effects of dapagliflozin in chronic kidney disease | 3.2 | 17 | Citations (PDF) |
| 51 | Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic Regions | 2.1 | 13 | Citations (PDF) |
| 52 | The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial | 2.7 | 25 | Citations (PDF) |
| 53 | The Kidney Protective Effects of the Sodium–Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor Antagonists | 2.1 | 64 | Citations (PDF) |
| 54 | Dialysis Initiation in Patients With Chronic Coronary Disease and Advanced Chronic Kidney Disease in ISCHEMIA‐CKD | 3.1 | 7 | Citations (PDF) |
| 55 | Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients | 8.3 | 70 | Citations (PDF) |
| 56 | The ASCEND-ND trial: study design and participant characteristics | 0.7 | 13 | Citations (PDF) |
| 57 | Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial | 4.8 | 64 | Citations (PDF) |
| 58 | Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials | 13.1 | 279 | Citations (PDF) |
| 59 | The Association Between Glycaemic Variability and Progression of Chronic Kidney Disease: a Systematic Review | 0.3 | 6 | Citations (PDF) |
| 60 | FC082: Effects of Dapagliflozin in Patients with Chronic Kidney Disease According to Background Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Dose | 0.7 | 0 | Citations (PDF) |
| 61 | FC 122: Effects of Canagliflozin on Cardiovascular and Kidney Events in Patients With Chronic Kidney Disease With and Without Peripheral Vascular Disease: Integrated Analysis From the Canvas Program and Credence Trial | 0.7 | 0 | Citations (PDF) |
| 62 | Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy | 15.8 | 336 | Citations (PDF) |
| 63 | Healthcare resource utilisation and related costs of patients with CKD from the UK: a report from the DISCOVER CKD retrospective cohort | 2.5 | 37 | Citations (PDF) |
| 64 | Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial | 3.1 | 9 | Citations (PDF) |
| 65 | Effects of Dapagliflozin in People without Diabetes and with Microalbuminuria | 3.0 | 5 | Citations (PDF) |
| 66 | New strategies to improve clinical outcomes for diabetic kidney disease | 4.4 | 78 | Citations (PDF) |
| 67 | Cost-Effectiveness of Dapagliflozin as a Treatment for Chronic Kidney Disease | 3.0 | 62 | Citations (PDF) |
| 68 | Glycaemic variability and progression of chronic kidney disease in people with diabetes and comorbid kidney disease: Retrospective cohort study | 2.0 | 21 | Citations (PDF) |
| 69 | Estimated Lifetime Benefit of Combined RAAS and SGLT2 Inhibitor Therapy in Patients with Albuminuric CKD without Diabetes | 3.0 | 79 | Citations (PDF) |
| 70 | Research engagement by British early-career practitioners in nephrology: a multidisciplinary survey | 1.2 | 3 | Citations (PDF) |
| 71 | Effects of Dapagliflozin in Patients Without Diabetes and Microalbuminuria: An Exploratory Analysis From the DAPA-CKD Trial | 0.3 | 0 | Citations (PDF) |
| 72 | Extrapolation of DAPA-CKD Trial End Points in a Broad Urine Albumin Creatinine Ratio Population | 0.3 | 1 | Citations (PDF) |
| 73 | APPETIZE: Palatability of and Preference for Potassium Binders in Patients With CKD and Hyperkalemia | 0.3 | 0 | Citations (PDF) |
| 74 | Routine serum biomarkers, but not dual-energy X-ray absorptiometry, correlate with cortical bone mineral density in children and young adults with chronic kidney disease | 0.7 | 25 | Citations (PDF) |
| 75 | “Epigenome-wide methylation profile of chronic kidney disease-derived arterial DNA uncovers novel pathways in disease-associated cardiovascular pathology.” | 2.1 | 14 | Citations (PDF) |
| 76 | Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease | 13.1 | 122 | Citations (PDF) |
| 77 | Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program | 1.0 | 64 | Citations (PDF) |
| 78 | Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice | 4.6 | 159 | Citations (PDF) |
| 79 | Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial | 12.5 | 502 | Citations (PDF) |
| 80 | The PrEscription of intraDialytic exercise to improve quAlity of Life in patients with chronic kidney disease trial: study design and baseline data for a multicentre randomized controlled trial | 2.5 | 20 | Citations (PDF) |
| 81 | Perspectives on blood pressure by patients on haemo‐ and peritoneal dialysis | 1.1 | 8 | Citations (PDF) |
| 82 | Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial | 2.6 | 112 | Citations (PDF) |
| 83 | Methods and rationale of the DISCOVER CKD global observational study | 2.5 | 24 | Citations (PDF) |
| 84 | Understanding and Overcoming the Challenges Related to Cardiovascular Trials Involving Patients with Kidney Disease | 3.0 | 15 | Citations (PDF) |
| 85 | MO559ASCEND-ND: STUDY DESIGN AND BASELINE CHARACTERISTICS | 0.7 | 1 | Citations (PDF) |
| 86 | FC 111THE SOCIETAL IMPACT OF DELAYED DIALYSIS INITIATION ASSOCIATED WITH DAPAGLIFLOZIN BASED ON THE RESULTS OF DAPA-CKD | 0.7 | 0 | Citations (PDF) |
| 87 | Time‐dependent lipid profile inversely associates with mortality in hemodialysis patients – independent of inflammation/malnutrition | 3.5 | 19 | Citations (PDF) |
| 88 | FC 089EFFECTS OF CANAGLIFLOZIN ON MAJOR ADVERSE CARDIOVASCULAR EVENTS BY BASELINE ALBUMINURIA: INTEGRATED ANALYSES FROM THE CANVAS PROGRAM AND CREDENCE TRIAL | 0.7 | 0 | Citations (PDF) |
| 89 | MO516A STRUCTURED EXPERT ELICITATION TO INFORM AND VALIDATE MORTALITY EXTRAPOLATIONS FOR A COST-EFFECTIVENESS ANALYSIS OF DAPAGLIFLOZIN | 0.7 | 1 | Citations (PDF) |
| 90 | The Potential Roles of Osmotic and Nonosmotic Sodium Handling in Mediating the Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Heart Failure | 0.9 | 31 | Citations (PDF) |
| 91 | A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy | 4.6 | 395 | Citations (PDF) |
| 92 | Heart Failure Hospitalization in Adults Receiving Hemodialysis and the Effect of Intravenous Iron Therapy | 3.0 | 21 | Citations (PDF) |
| 93 | Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease | 0.3 | 191 | Citations (PDF) |
| 94 | Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial | 2.6 | 116 | Citations (PDF) |
| 95 | Randomized Trial—PrEscription of intraDialytic exercise to improve quAlity of Life in Patients Receiving Hemodialysis | 2.1 | 47 | Citations (PDF) |
| 96 | Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure | 3.0 | 86 | Citations (PDF) |
| 97 | Stroke in Hemodialysis Patients Randomized to Different Intravenous Iron Strategies: A Prespecified Analysis from the PIVOTAL Trial | 1.4 | 13 | Citations (PDF) |
| 98 | Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial | 12.5 | 188 | Citations (PDF) |
| 99 | Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial | 12.5 | 192 | Citations (PDF) |
| 100 | Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis | 19.4 | 219 | Citations (PDF) |
| 101 | Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis | 19.4 | 210 | Citations (PDF) |
| 102 | Association of changes in bone mineral parameters with mortality in haemodialysis patients: insights from the ARO cohort | 0.7 | 31 | Citations (PDF) |
| 103 | Prediction of the effect of dapagliflozin on kidney and heart failure outcomes based on short-term changes in multiple risk markers | 0.7 | 11 | Citations (PDF) |
| 104 | Recurrent hyperkalaemia management and use of renin–angiotensin–aldosterone system inhibitors: a European multi-national targeted chart review | 2.5 | 20 | Citations (PDF) |
| 105 | Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference | 4.6 | 447 | Citations (PDF) |
| 106 | 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD | 2.6 | 3,677 | Citations (PDF) |
| 107 | Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7% | 13.1 | 115 | Citations (PDF) |
| 108 | Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial | 12.5 | 118 | Citations (PDF) |
| 109 | Correction of anemia by dapagliflozin in patients with type 2 diabetes | 1.8 | 42 | Citations (PDF) |
| 110 | Dapagliflozin in Patients with Chronic Kidney Disease | 19.4 | 5,133 | Citations (PDF) |
| 111 | Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2 | 3.0 | 135 | Citations (PDF) |
| 112 | KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantation | 4.6 | 19 | Citations (PDF) |
| 113 | KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer | 4.6 | 46 | Citations (PDF) |
| 114 | The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics | 0.7 | 174 | Citations (PDF) |
| 115 | HEROIC: a 5-year observational cohort study aimed at identifying novel factors that drive diabetic kidney disease: rationale and study protocol | 1.2 | 4 | Citations (PDF) |
| 116 | Estradiol and mortality in women with end-stage kidney disease | 0.7 | 13 | Citations (PDF) |
| 117 | MO016MYOCARDIAL INFARCTION IN THE PIVOTAL STUDY OF IV IRON IN HAEMODIALYSIS: A PRE-SPECIFIED SECONDARY ANALYSIS | 0.7 | 0 | Citations (PDF) |
| 118 | Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial | 0.3 | 149 | Citations (PDF) |
| 119 | Hospitalization and mortality following non-attendance for hemodialysis according to dialysis day of the week: a European cohort study | 1.5 | 16 | Citations (PDF) |
| 120 | P0816CLINICAL CHARACTERISTICS AND EGFR AND UACR DISTRIBUTION ACCORDING TO THE 2012 KDIGO CKD CLASSIFICATION: A REPORT FROM THE US DISCOVER CKD COHORT | 0.7 | 0 | Citations (PDF) |
| 121 | Patient and Caregiver Perspectives on Terms Used to Describe Kidney Health | 3.0 | 56 | Citations (PDF) |
| 122 | MO015HAEMODIALYSIS VASCULAR ACCESS THROMBOSIS: AN ANALYSIS OF EVENTS FROM THE PROACTIVE IV IRON THERAPY IN HAEMODIALYSIS PATIENTS (PIVOTAL) TRIAL | 0.7 | 0 | Citations (PDF) |
| 123 | Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial | 0.7 | 204 | Citations (PDF) |
| 124 | Identifying critically important cardiovascular outcomes for trials in hemodialysis: an international survey with patients, caregivers and health professionals | 0.7 | 12 | Citations (PDF) |
| 125 | SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes | 2.2 | 36 | Citations (PDF) |
| 126 | Patient and Caregiver Priorities for Outcomes in CKD: A Multinational Nominal Group Technique Study | 1.0 | 100 | Citations (PDF) |
| 127 | Sodium-glucose cotransporter 2 inhibitor effects on cardiovascular outcomes in chronic kidney disease | 0.7 | 10 | Citations (PDF) |
| 128 | Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories | 3.0 | 79 | Citations (PDF) |
| 129 | Survival on four compared with three times per week haemodialysis in high ultrafiltration patients: an observational study | 2.5 | 7 | Citations (PDF) |
| 130 | Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups | 13.1 | 255 | Citations (PDF) |
| 131 | FC060THE ASSOCIATION BETWEEN FOUR TIMES A WEEK COMPARED TO THREE TIMES A WEEK HAEMODIALYSIS AND SURVIVAL, HOSPITALISATION AND VASCULAR ACCESS COMPLICATIONS IN EUROPEAN IN-CENTRE PATIENTS | 0.7 | 0 | Citations (PDF) |
| 132 | SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis | 12.5 | 821 | Citations (PDF) |
| 133 | Chronic kidney disease and valvular heart disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference | 4.6 | 140 | Citations (PDF) |
| 134 | Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial | 12.5 | 188 | Citations (PDF) |
| 135 | Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference | 4.6 | 431 | Citations (PDF) |
| 136 | Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy | 19.4 | 5,704 | Citations (PDF) |
| 137 | New pharmacological strategies for protecting kidney function in type 2 diabetes | 12.5 | 80 | Citations (PDF) |
| 138 | Intravenous Iron in Patients Undergoing Maintenance Hemodialysis | 19.4 | 472 | Citations (PDF) |
| 139 | Cinacalcet-induced hypocalcemia in a cohort of European haemodialysis patients: predictors, therapeutic approaches and outcomes | 1.2 | 12 | Citations (PDF) |
| 140 | Scope and Consistency of Outcomes Reported in Randomized Trials Conducted in Adults Receiving Hemodialysis: A Systematic Review | 1.0 | 49 | Citations (PDF) |
| 141 | Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference | 2.6 | 252 | Citations (PDF) |
| 142 | Risk Factors for Prognosis in Patients With Severely Decreased GFR | 2.1 | 42 | Citations (PDF) |
| 143 | Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kidney disease | 0.7 | 84 | Citations (PDF) |
| 144 | Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation | 4.6 | 39 | Citations (PDF) |
| 145 | FP634HIGH ALL CAUSE AND CVD MORTALITY IN AN INCIDENT COHORT OF HEMODIALYSIS PATIENTS WITH LOW SERUM ALBUMIN AND INFLAMMATION | 0.7 | 0 | Citations (PDF) |
| 146 | FP366OUTCOMES OF PEOPLE WITH CHRONIC KIDNEY DISEASE STAGES 3-5 MANAGED IN PRIMARY CARE IN THE UK - FINDINGS FROM THE NATIONAL CKD AUDIT | 0.7 | 0 | Citations (PDF) |
| 147 | FP657STAKEHOLDER PRIORITIES FOR CARDIOVASCULAR OUTCOMES IN HEMODIALYSIS TRIALS: AN INTERNATIONAL SURVEY | 0.7 | 1 | Citations (PDF) |
| 148 | SaO066THE VARIATION IN HOSPITALISATION AND MORTALITY FOLLOWING NON-ATTENDANCE FOR HAEMODIALYSIS ACCORDING TO DIALYSIS DAY OF THE WEEK IN A EUROPEAN COHORT: FURTHER EVIDENCE OF HARM FROM THE TWO-DAY BREAK IN THREE TIMES A WEEK HAEMODIALYSIS | 0.7 | 1 | Citations (PDF) |
| 149 | SaO027CHANGES IN BONE-MINERAL PARAMETERS PREDICT SUBSEQUENT MORTALITY IN HEMODIALYSIS PATIENTS - INSIGHTS FROM THE EUROPEAN ARO-COHORT | 0.7 | 0 | Citations (PDF) |
| 150 | Clinicians’ and researchers’ perspectives on establishing and implementing core outcomes in haemodialysis: semistructured interview study | 1.2 | 12 | Citations (PDF) |
| 151 | Fibroblast Growth Factor-23 and Risks of Cardiovascular and Noncardiovascular Diseases: A Meta-Analysis | 0.3 | 177 | Citations (PDF) |
| 152 | Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kidney disease | 0.7 | 18 | Citations (PDF) |
| 153 | The National CKD Audit: a primary care condition that deserves more attention | 0.6 | 14 | Citations (PDF) |
| 154 | Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease | 13.1 | 231 | Citations (PDF) |
| 155 | How do primary care doctors in England and Wales code and manage people with chronic kidney disease? Results from the National Chronic Kidney Disease Audit | 0.7 | 47 | Citations (PDF) |
| 156 | Nephrologists’ Perspectives on Defining and Applying Patient-Centered Outcomes in Hemodialysis | 3.0 | 46 | Citations (PDF) |
| 157 | Developing a Set of Core Outcomes for Trials in Hemodialysis: An International Delphi Survey | 1.0 | 285 | Citations (PDF) |
| 158 | Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy | 45.2 | 856 | Citations (PDF) |
| 159 | Accounting for overdispersion when determining primary care outliers for the identification of chronic kidney disease: learning from the National Chronic Kidney Disease Audit | 0.7 | 6 | Citations (PDF) |
| 160 | Evidence for Reverse Causality in the Association Between Blood Pressure and Cardiovascular Risk in Patients With Chronic Kidney Disease | 4.7 | 36 | Citations (PDF) |
| 161 | Reducing major risk factors for chronic kidney disease | 2.7 | 213 | Citations (PDF) |
| 162 | Complications of chronic kidney disease: current state, knowledge gaps, and strategy for action | 2.7 | 224 | Citations (PDF) |
| 163 | Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease—Improving Global Outcomes (KDIGO) Controversies Conference | 4.6 | 140 | Citations (PDF) |
| 164 | The role of trimethylamine N-oxide as a mediator of cardiovascular complications in chronic kidney disease | 4.6 | 111 | Citations (PDF) |
| 165 | Sex Hormone Status in Women With Chronic Kidney Disease: Survey of Nephrologists’ and Renal Allied Health Care Providers’ Perceptions | 0.9 | 34 | Citations (PDF) |
| 166 | SO019EFFECTS OF EMPAGLIFLOZIN ON CARDIOVASCULAR OUTCOMES ACROSS KDIGO RISK CATEGORIES: RESULTS FROM THE EMPA-REG OUTCOME® TRIAL | 0.7 | 3 | Citations (PDF) |
| 167 | SP259EFFECTS OF EMPAGLIFLOZIN ON RENAL OUTCOMES ACROSS KDIGO RISK CATEGORIES: RESULTS FROM THE EMPA-REG OUTCOME® TRIAL | 0.7 | 4 | Citations (PDF) |
| 168 | The VITAH Trial—Vitamin D Supplementation and Cardiac Autonomic Tone in Patients with End-Stage Kidney Disease on Hemodialysis: A Blinded, Randomized Controlled Trial | 3.2 | 13 | Citations (PDF) |
| 169 | SP285MORE THAN ONE THIRD OF RENAL PATIENTS UNDER PRIMARY CARE IN THE UK ARE NOT RECEIVING THE RECOMMENDED STATIN THERAPY FOR PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE | 0.7 | 0 | Citations (PDF) |
| 170 | MP313IDENTIFYING OUTLYING PRACTICES IN PREVALENCE OF CKD IN PRIMARY CARE | 0.7 | 0 | Citations (PDF) |
| 171 | Patient and Caregiver Priorities for Outcomes in Hemodialysis: An International Nominal Group Technique Study | 1.0 | 286 | Citations (PDF) |
| 172 | A Fine Balance: Developing Clinical Practice Guidelines in Areas Where Evidence is Lacking | 0.8 | 7 | Citations (PDF) |
| 173 | FP003ACHIEVEMENT AND MAINTENANCE OF NORMOKALAEMIA IN PATIENTS WITH NON-DIALYSIS STAGE 5 CHRONIC KIDNEY DISEASE | 0.7 | 1 | Citations (PDF) |
| 174 | Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis | 45.2 | 370 | Citations (PDF) |
| 175 | The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis | 3.0 | 91 | Citations (PDF) |
| 176 | Vitamin D Supplementation Is Associated With Stabilization of Cardiac Autonomic Tone in IgA Nephropathy | 4.7 | 10 | Citations (PDF) |
| 177 | Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis | 13.1 | 305 | Citations (PDF) |
| 178 | High cardiovascular event rates occur within the first weeks of starting hemodialysis | 4.6 | 108 | Citations (PDF) |
| 179 | Kidney Disease: Improving Global Outcomes--an update | 0.7 | 26 | Citations (PDF) |
| 180 | Inflammatory stress reduces the effectiveness of statins in the kidney by disrupting HMGCoA reductase feedback regulation | 0.7 | 13 | Citations (PDF) |
| 181 | Is Intensive Blood Pressure Lowering Justifiable in CKD? | 1.0 | 1 | Citations (PDF) |
| 182 | Summary of KDIGO guideline. What do we really know about management of blood pressure in patients with chronic kidney disease? | 4.6 | 158 | Citations (PDF) |
| 183 | The Management of Dyslipidemia in CKD: New Analyses of an Expanding Dataset | 1.0 | 8 | Citations (PDF) |
| 184 | Tuberculous pyomyositis in a renal transplant recipient | 2.5 | 2 | Citations (PDF) |
| 185 | Alanine-Glyoxylate Aminotransferase-2 Metabolizes Endogenous Methylarginines, Regulates NO, and Controls Blood Pressure | 4.3 | 80 | Citations (PDF) |
| 186 | Community-Based Strategies for Blood Pressure Control in Low-Income Countries | 1.0 | 0 | Citations (PDF) |
| 187 | The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial | 45.2 | 2,372 | Citations (PDF) |
| 188 | Serum Free Light Chains and the Risk of ESRD and Death in CKD | 3.0 | 39 | Citations (PDF) |
| 189 | Editorial report 2010 | 0.7 | 4 | Citations (PDF) |
| 190 | Fish consumption and prostate cancer risk: a review and meta-analysis | 3.4 | 186 | Citations (PDF) |
| 191 | The five most cited NDT papers from 2005 to 2009 | 0.7 | 0 | Citations (PDF) |
| 192 | The Jupiter trial—new territory for statins?* | 0.7 | 2 | Citations (PDF) |
| 193 | Mesangial matrix-activated mononuclear cells express functional scavenger receptors and accumulate intracellular lipid | 1.7 | 0 | Citations (PDF) |
| 194 | Report from the Editorial Office | 0.7 | 2 | Citations (PDF) |
| 195 | Salt wars | 0.7 | 2 | Citations (PDF) |
| 196 | Mesangial matrix-activated monocytes express functional scavenger receptors and accumulate intracellular lipid | 0.7 | 6 | Citations (PDF) |
| 197 | Report from the editorial office | 0.7 | 3 | Citations (PDF) |
| 198 | CARDIOVASCULAR AND SURVIVAL PARADOXES IN DIALYSIS PATIENTS: Misleading Associations between Cholesterol and Vascular Outcomes in Dialysis Patients: The Need for Randomized Trials | 0.8 | 26 | Citations (PDF) |
| 199 | Which issues should trials address in hemodialysis? | 0.8 | 0 | Citations (PDF) |
| 200 | Cardiovascular complications of chronic kidney disease | 0.3 | 2 | Citations (PDF) |
| 201 | NDT contributes to a collection of 100 seminal papers published by Oxford University Press | 0.7 | 0 | Citations (PDF) |
| 202 | Mechanisms of Dysregulation of Low-Density Lipoprotein Receptor Expression in Vascular Smooth Muscle Cells by Inflammatory Cytokines | 4.3 | 109 | Citations (PDF) |
| 203 | Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study | 1.0 | 294 | Citations (PDF) |
| 204 | Transjugular kidney biopsy | 1.0 | 60 | Citations (PDF) |
| 205 | Monocyte adhesion to mesangial matrix modulates cytokine and metalloproteinase production | 4.6 | 33 | Citations (PDF) |
| 206 | Cardiovascular Complications of Chronic Kidney Disease | 0.3 | 1 | Citations (PDF) |
| 207 | PPAR Agonists Protect Mesangial Cells from Interleukin 1β-Induced Intracellular Lipid Accumulation by Activating the ABCA1 Cholesterol Efflux Pathway | 0.3 | 108 | Citations (PDF) |
| 208 | Synthesis of 1,25-Dihydroxyvitamin D3 by Human Endothelial Cells Is Regulated by Inflammatory Cytokines | 0.3 | 298 | Citations (PDF) |
| 209 | A randomized double-blind placebo-controlled trial of the effect of homocysteine-lowering therapy with folic acid on endothelial function in patients with coronary artery disease | 0.7 | 84 | Citations (PDF) |
| 210 | Premature cardiovascular disease in chronic renal failure | 45.2 | 519 | Citations (PDF) |
| 211 | 10.1016/b978-0-323-04602-2.50073-4 | 0.0 | 0 | Citations (PDF) |
| 212 | Ischaemic heart disease after renal transplantation: how to assess and minimize the risk | 0.7 | 8 | Citations (PDF) |
| 213 | Vancomycin-dependent enterococci in a uraemic patient with sclerosing peritonitis | 0.7 | 15 | Citations (PDF) |
| 214 | Case of propylthiouracil-induced ANCA associated small vessel vasculitis | 0.7 | 20 | Citations (PDF) |
| 215 | Renal amyloidosis and angioimmunoblastic lymphadenopathy | 0.7 | 4 | Citations (PDF) |
| 216 | Cardiovascular risk factors in patients with chronic renal failure 1997, 7, 182-186 | | 2 | Citations (PDF) |
| 217 | Listeria monocytogenes CAPD peritonitis: failure of vancomycin therapy | 2.1 | 13 | Citations (PDF) |
| 218 | Characterisation of the Binding of Low-Density Lipoproteins to Cultured Rat Mesangial Cells | 0.7 | 40 | Citations (PDF) |
| 219 | Effects of dietary fatty acids in an animal model of focal glomerulosclerosis | 4.6 | 27 | Citations (PDF) |
| 220 | Experience with a New Method for Percutaneous Renal Biopsy | 0.7 | 57 | Citations (PDF) |
| 221 | Effects of Low-Density Lipoproteins on Mesangial Cell Growth and Viability In Vitro | 0.7 | 43 | Citations (PDF) |
| 222 | Dietary Fish Oil Supplements Preserve Renal Function in Renal Transplant Recipients with Chronic Vascular Rejection | 0.7 | 0 | Citations (PDF) |
| 223 | Recurrent Acute Renal Failure with Interstitial Nephritis Due to D-Penicillamine | 1.8 | 12 | Citations (PDF) |
| 224 | Scoping Review—Diabetes Technology for Individuals on Kidney Replacement Therapy (Dialysis): Current Trends and Future Directions | 2.2 | 3 | Citations (PDF) |
| 225 | Effects of Dapagliflozin on Progression of CKD According to Different Rates of Pretrial eGFR Loss | 3.0 | 1 | Citations (PDF) |
| 226 | Diabetic eye screening in people with diabetes undergoing haemodialysis: A systematic review and meta‐analysis | 1.7 | 2 | Citations (PDF) |
| 227 | Incidence and risk factors for chronic kidney disease in individuals with type 1 diabetes: A population‐based study in Salford, Manchester | 1.7 | 2 | Citations (PDF) |
| 228 | Vitamin K Epoxide Reductase Complex Subunit 1 (VKORC1) Gene Polymorphisms Predict Arterial Stiffness and Serum MGP Levels in Chronic Kidney Disease Patients | 1.8 | 3 | Citations (PDF) |
| 229 | Associations of chronic kidney disease with recurrent stroke in patients with intracerebral haemorrhage | 2.9 | 1 | Citations (PDF) |
| 230 | A Hierarchical Composite Endpoint for CKD Progression in Patients with FSGS | 3.0 | 1 | Citations (PDF) |
| 231 | Unravelling dialysis‐related dysglycaemia: Longitudinal insights from continuous glucose monitoring | 1.7 | 0 | Citations (PDF) |
| 232 | Efficacy and safety of dapagliflozin in patients receiving dialysis: a post-hoc analysis of the DAPA-CKD trial | 2.5 | 0 | Citations (PDF) |
| 233 | CV risk: if you aren’t testing ACR, you aren’t seeing the full picture | 1.5 | 0 | Citations (PDF) |
| 234 | New insights from DAPA-CKD indicate dapagliflozin modulates key pathways related to kidney outcomes | 4.6 | 0 | Citations (PDF) |
